Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (171-180 of 235) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Pageof 24

Showing results (171-180 of 235) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Pageof 24